by Tom Salemi
Their searches have led them primarily to Europe, where a shared history and far more predictable regulatory path beckon. Start-ups...
Device Companies Look West, East, Anyplace But US
Listen to this article
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
Candid conversations with C-suite leaders.
More from Global Vision
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
- • By
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
- • By
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.